Tuberculin Purified Protein Derivative

DRUG3 trials

Sponsors

National Institute of Allergy and Infectious Diseases (NIAID), Assiut University, National Heart, Lung, and Blood Institute (NHLBI)

Conditions

Common WartHIV InfectionsHealthyLatent Tuberculosis Infection (LTBI)Tuberculosis

Early Phase 1

Characterization of Tissue-Specific Immune Responses to Bronchoscopic Instillation of Mycobacterial Antigens Into the Human Lung

CompletedNCT05027958

National Heart, Lung, and Blood Institute (NHLBI)Healthy, Latent Tuberculosis Infection (LTBI)

Start: 2022-05-03End: 2024-12-08Updated: 2026-05-27

Phase 3

Efficacy of Cryotherapy Combined With Intralesional Tuberculin PPD Versus Intralesional Tuberculin PPD in Treatment of Multiple Common Warts

Assiut UniversityCommon Wart

Start: 2020-03-01End: 2021-05-01Target: 40Updated: 2020-02-28

Unknown Phase

Two-Stage Tuberculin (PPD) Skin Testing in Individuals With Human Immunodeficiency Virus (HIV) Infection

CompletedNCT00000955

National Institute of Allergy and Infectious Diseases (NIAID)HIV Infections, Tuberculosis

End: 1992-12-31Target: 864Updated: 2013-10-01

Related Papers

Efficacy of Cryotherapy Combined With Intralesional Purified Protein Derivative (PPD) Versus Intralesional PPD Monotherapy in the Treatment of Multiple Common Warts

Journal of Cutaneous Medicine and Surgery2023-01-275 citations